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Abstract: Epilepsy is one of the most common neurological disorder in the world. Many antiepileptic 
drugs cause multiple adverse effects. Moreover, multidrug resistance is a serious problem in epilepsy 
treatment. In the present study we evaluated the safety profile of three (1- 3) new chiral N-aminoalkyl 
derivatives of trans-2-aminocyclohexan-1-ol demonstrating anticonvulsant activity. Our aim was also 
to determine differences between the enantiomeric compounds with respect to their safety profile. 
The results of the study indicated that compounds 1- 3 are non-cytotoxic for astrocytes, although 
they exhibit cytotoxic activity against human glioblastoma cells. Moreover, 1- 3 did not affect the 
viability of HepG2 cells and did not produce adducts with glutathione. Compounds 1- 3 demonstrated 
no mutagenic activity either in the Salmonella typhimurium  or in Vibrio harveyi tests. Additionally, 
the compounds displayed a strong or moderate antimutagenic effect. Finally, the P-glycoprotein 
(P-gp) ATPase assay demonstrated that both enantiomers are potent P-gp inhibitors. To sum up, 
our results indicate that the newly synthesized derivatives may be considered promising candidates 
for further research on anticonvulsant drug discovery and development. Our study indicated the 
similar safety profile of the enantiomeric N-aminoalkyl derivatives of trans-2-aminocyclohexan-1-ol, 
although in the previous studies both enantiomers differ in their biotransformation pathways and 
pharmacological activity.
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1. Introduction
Epilepsy is one of the most common neurological disorder in the world. Despite advanced studies 
on antiepileptic therapies, there is still a lack of effective drugs that are appropriate for patients. 
The most important challenges in epilepsy treatment include the multiple and serious adverse effects 
of the currently available antiepileptic drugs (AEDs) and multidrug resistance (MDR) [1- 5].
In the search for new agents that possess antiepileptic activity, we turned our attention to 
aminocyclohexanol derivatives that exhibit potent central nervous system (CNS) activity [6- 8]. In the 
previous study we described the synthesis, in vivo anticonvulsant activity, and in vitro metabolism of 
three new chiral N-aminoalkyl derivatives of trans-2-aminocyclohexan-1-ol, denoted as 1 (R enantiomer),
2 (S enantiomer), and 3 (racemate) (Figure 1) [9]. These compounds were proved to be active 
anticonvulsants in a maximal electroshock test (MES) performed at the National Institute of Health 
(Rockville, USA) within the Antiepileptic Drug Development Program [10]. In particular, R enantiomer
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exhibited anti-MES activity with a protective index (PI) of 1.72 (mice, i.p.), whereas racemate showed 
PI value of 2.83 (mice, i.p.) (Table 1) [9]. Moreover, biotransformation analysis of compounds 1-3 
performed in the liver microsome system demonstrated that enantiomers R and S undergo different 
biotransformation pathways, which could explain their therapeutic potential and toxicity [9].
Figure 1. Chemical structures of the title compounds (1-3).
Table 1. Anticonvulsant quantification results (in vivo study) [9].
Compound Dose (mg/kg) TDsoa ED50(MES) b PI(MES)
1 30 66.03 #
38.34 # 1.722#
100 66.°3 #scMet > 90.00 #scMet < 1.722 #scMet
2 30 n.d. n.d. n.d.100 n.d. n.d. n.d.
30 71.04# 25.05 # 2.839 #
3 100 71.°4 #scMet >150 #scMet <0.474 #scMet
300 >250" 99.25 " 2.519 "
PHT
34.45 # 6.48 # 6.60 #















a Dose of the compound that produces toxicity in 50% of tested animals;b dose of the compound that gives protection 
against seizures toxicity in 50% of tested animals. # Values for mice after i.p. administration. " Values for rats after 
p.o. administration; n.d.—not determined. Anticonvulsant quantification were determined only for compounds 
1 and 3, which display sufficient antiepileptic activity and low neurotoxicity in the primary evaluations; PHT: 
phenytoin, BZ: carbamazepine, VPA: valproate.
In light of the aforementioned findings and continuing our study of three active chiral N-aminoalkyl 
derivatives of trans-2-aminocyclohexan-1-ol, the present work was focused on in vitro cytotoxicity 
evaluation and understanding the basic mechanisms that underlie compounds 1-3 activity. In particular, 
we established the safety profile of 1-3 by performing cellular cytotoxicity analysis using CNS cells and 
mutagenicity assays with the bacterial strains Salmonella typhimurium and Vibrio harveyi. As many AEDs 
are known to demonstrate hepatotoxic effects, we also evaluated the hepatotoxicity of compounds 1-3, 
both in a HepG2 cellular model and in a human liver microsome system in the presence of glutathione. 
Additionally, the antimutagenic effects of test substances were determined.
MDR has been described in many patients receiving anticonvulsant treatment. One frequently 
described mechanism of this phenomenon is overexpression of ATP-binding cassette (ABC) transporters 
at the blood-brain barrier. High ABC transporter expression is largely responsible for the fact that
anticonvulsant drugs are pumped out of their target site of action [11]. P-glycoprotein (P-gp) plays a 
crucial role in drug absorption and brain uptake, and many studies have demonstrated that several 
AEDs could be P-gp substrates or inhibitors [5,12- 15]. Therefore, within the present paper, the ability 
of compounds 1-3 to modulate P-gp ATPase activity was assessed to clarify the interactions between 
the investigated compounds and P-gp and to evaluate their potential as new drug candidates for 
treating MDR epilepsy.
Finally, our aim was to determine differences between the enantiomeric N-aminoalkyl derivatives 
of trans-2-aminocyclohexan-1-ol with respect to their safety profile.
2. Results and Discussion
2.1. Cytotoxicity
AEDs are fraught with numerous undesirable effects, of which cytotoxicity is one of the most 
serious [16- 20]. Therefore, in this work we focused our attention on assessing the active compounds' 
(1-3) cytotoxicity in relation to CNS cells. A typical model for neurotoxicity evaluation commonly 
used in publications are human neuroblastoma SH-SY5Y cells. Considering the fact that the cells of 
this line are transformed, they have a cancerous origin. Therefore, within this work we decided to 
investigate the safety profile of compounds 1-3 on a normal cell line i.e., astrocytes. Astrocytes are 
specialized glial cells that contiguously tile the entire central nervous system and play a crucial role 
in CNS [21]. Interestingly, astrocytes are also vulnerable to seizures, as shown by Gualtieri et al. [22] 
and reviewed in Curia et al. [23]. Moreover, astrocytes have been used successfully in safety profile 
analysis of different compounds [24- 27].
The results obtained using the M TT assay demonstrated that none of the tested compounds 
induced a significant cytotoxic effect on the normal astrocyte cell line in a concentration range of 
10-100 gM, while glioblastoma cells incubated with higher concentrations of both enantiomers lose 
viability in a dose-dependent manner (Figure 2). The racemic compound was less cytotoxic than the 
two enantiomers. Moreover, the results of the M TT test are comparable with those obtained in the 
LDH assay (Figure 3). Matysiak et al., who examined the cytotoxicity of (R)- and (S)-ricinoleic acid 
amides and their acetates, revealed that both enantiomers of the ethanolamine-derived amides showed 
promising anticancer potential [28]. On the other hand, in the study of praziquantel enantiomers it 
was indicated that both enantiomers differ in their cytotoxicity profile [29]. Similarly, according to 
Tokunaga et al. the enantiomeric forms of fluoro-thalidomide displayed different anti-tumor activities, 
with the (S)-enantiomer being noticeably more potent [30].
compound concentration ( pM)
(a)
Figure 2. Cont.
I?igure 2. Effect of compounds 1, 2, and 3 on viability of astrocytes (a) and human glioma cells (b). 
Cells were cultured in medium supplemented with 10% FBS and antibiotics in the presence or absence 
(control) of compounds (10, 25,50, or 100 pM). After 24 h incubation, the MTT assay? was performed. 
Doxorubicin (DOX) was used as a positive control. Results from the MTT assay are presented as 
percent of1 living cells compared to the control. Values represent means ± SEM of three independent 
experiments (p < 0.05).
Figure 3. Cytotoxicity of compounds 1, 2, and 3 on astrocytes and human glioma cells. Cells were 
cultured in medium supplemented with 10% FBS and antibiotics in the presence of compounds (10, 25,
50, or 100 gM). Results from LDH assays show the percent of cytotoxicity compared to the control. 
Values repretent means ± SEM od three independent experiments (p < 0.05).
The observed selectivity of 1-3 towards different cell lines is particularly interesting and opens up 
new prospects for research on their activity. Cytoto±ic activity of tested trans-2-aminocyclohexan-1-ol 
derivatives with chiral carbon atoms agninst tumor cells may be vital in the context of their potential 
chemopreventive action. The anti-cancer activity of anti-epileptic drugs has previously been described 
in the literature; however, there have been no reports concerning compound selectivity. Interestingly, 
valproic acid prodrug was used to increase the sensitivity of neoplastic cells to doxorubicin therapy [31]. 
In another study, Kwiecińska et al. demonstrated that co-treatment with valproic acid increased the 
efficiency of doxorubicin, carboplatin, and cyclophosphamide in various ovarian cancer cell lines [32].
2.2. Hepatotoxicity, Metabolic Activation and Trapping Assay
Drug-induced liver injury is the most common cause of liver injury and a serious clinical problem. 
Therefore, within the present paper compounds 1- 3 wene evaluated in vitro for their hepatotoxicity 
on human liver cancer cehs (HepG2) in the MTT vrnbility assay. As shown in Figure 4, tj e tested 
compounds did not affec i the viability of HepG2 cells at concentrations up to 100 |oM. Moreover, they 
did not affeft the cellular morphology ofter 24 h incubation, even at the highest concentration used in 
the experiment (Fignre e).
Control Compd 1 Compd 2 Compd 3
Figure 4. Hepatotoxicity of 1,12, and (3. Cells were cultured in medium supplemented with 10% FBS 
in the absence or presence of compounds (10, 25, 50, or 100 |M). Alter 2/1 h incubation, pictures of 
cells were taken using bright field microscope (a) and the MTT assay (It)) was performed. Reoults from 
the MTT assay show the percent of ljving (metabolically active) cells. Values represent means ± SEM 
o f three independent experimenls (p <  0.05) . Valproic acid was used as positive control. Metabolic 
activation and trapping assay (c); representative chromatogram of 1 and ils metaboliees following 
incubation of 1 with human liver mirroromes oupplemnnted with NADPH nnd reduced glutathione. 
Molecular masses of the [M + H]+ ions of metabolitea are shown.
Many xenobiotics are known to display hepatotoxic activity, resulting not only rrom their direct 
fiction, but also from their biotransformation to reactive intermediates [33,34]. Such properties fire 
characteristic of classical AED s, such as valproic acid, which is biorransformed fo a toxic metabolite 
4-ene-valproic acid. The hepatotoxicity of i-ent-palproic acid contributes to the developm enj of 
liver injury [35]. Electrophiles that occur during metabolism form conjugates with intracellular 
ntacronfolecules and constituents of the antioxidant system (primarily with glutathione); this causes 
iis depletion and. contributes fo hepafocytes necrosis. For these; reasons, early drug development 
processes include strategies for the detection of reactjve metabolites by means of trapping assays with 
glutathione [36- 38] .
Compounds 1- 3 were examined for the production of foxic metabolites in order fo predict their 
hepatotoxic potential. Incubations of te it compounds with glutathione gave sevetal peaks that were 
attributed entirely fo the remaining parent compound. The main metabolites were the products of 
aliphatic hydroxylation (m/z 300) and carbonylation (mfz 298 and m/z 316) (Figure 5). The representative
chromatogram of R enantiomer and its metabolites following incubation with human liver microsomes 
(HLMs) supplemented with NADPH and glutathione is presented in Figure 4 . As compounds 1-3 did 
not produce any adducts with glutathione in the human liver microsome system, probably they can be 
classified as safe with respect to their metabolic fate. These results are consistent with previous reports 
relating to in vitro biotransformation of compounds 1-3 with rat liver microsomes [9].
Figure 5. Chemical structures of the main metabolites of compounds 1-3.
2.3. Mutagenicity andAntimutagenicity
Mutagenic activity is one of the most important endpoints for risk assessment of chemical 
compounds including; booth drug substances and drug; candidates. Mutagenic agents are capable of 
inducing unfavorable effects on genetic mateoial of a cell [39]. As regards chiral compounds, enantiomers 
may possess different carcinogenicity and teratogeniaity [40]. On the other hand, the mutagenic properties 
of some chemicals may be partly modulated or reduced by using; agents possessing antimutagenic 
activity; [41].
In the present papsr, mutagenicity and antimutagenicity of 1-3 were evaluated using two microbial 
systems i.e., Salmonella typhimurium and Vibiio hawayi. According to our findings; the racemic comdound 
ond both enantiomers demonstrated no mutagenic activity either in -tine TA100 strain of S. typhimurium 
or in the strains of V. harveyi (BB7, BB0M, BB7X, and BB7XM) (Tables 2 and 3]). A dditional^, the 
investigated compounds displayed a strong or moderate antimutagenic effect on chemically induced 
mutagenesis in S. typhimurium and V. harveyi strains (Tables 2 and 3). To determine the antimutagenic 
activity, a direct mutagen nitroquinoline-N-oxide (NQNO) was used. NQNO is a base substitution 
agent, principally acting; ort G residues, inducing mainly GC to AT transitions t42]. The obaerved 
protectfen of tine baaterial genome against NQNO damage may be a result of the inhibition of the 
interaction between DNA and a mutagen [41,43]. However, more studtes are needed to confirm 
this hypothesis.
Table 2. Mutagenic activity of tested compounds in the Ames and the Vibrio harveyi tests.
Compound
Ames Test Vibrio harveyi Test
TA100 a BB7 a BB7X a BB7M a BB7XM a
Mean ± SD MI b Mean ± SD MI b Mean ± SD MI b Mean ± SD MI b Mean ± SD MI b
H2O 8 ± 3 19 ± 4 17 ± 6 22 ± 3 9 ± 4
DMSO 16 ± 5 16 ± 3 13 ± 4 16 ± 2 11 ± 4
NQNO 33 ± 4 2.1 32 ± 4 2.0 26 ± 2 2.0 32 ± 2 2.0 24 ± 3 2.2
1 9 ± 4 0.6 21 ± 3 1.1 16 ± 5 0.9 22 ± 3 1.0 18 ± 2 1.6
2 3 ± 1 0.2 23 ± 5 1.2 10 ± 6 0.6 23 ± 3 1.1 10 ± 3 0.9
3 6 ± 3 0.4 23 ± 3 1.4 13 ± 4 1.0 27 ± 4 1.7 15 ± 4 1.4
a Number of revertants; NQNO (nitroquinoline-N-oxide, 40 ng/mL) was used as a positive control; DMSO and H2O were used as a negative control; b MI (mutagenic index): number of 
induced revertants/number of spontaneous revertants (positive assay when MI > 2).
Table 3. Antimutagenic activity of compounds 1-3 in the Ames and the Vibrio harveyi tests.
Compound
Ames Test Vibrio harveyi Test
TA100 a BB7 a BB7X a BB7M a BB7XM a
Mean ± SD Inhib. (%)b Mean ± SD Inhib. (%) b Mean ± SD Inhib. (%) b Mean ± SD Inhib. (%) b Mean ± SD Inhib. (%) b
H2O 5 ± 2 12 ± 2 11 ± 4 16 ± 3 13 ± 4
DMSO 6 ± 2 14 ± 3 13 ± 3 10 ± 2 15 ± 3
NQNO 22 ± 4 38 ± 5 29 ± 4 35 ± 3 24 ± 4
1 16 ± 2 (27) 26 ± 3 (32) 20 ± 4 (31) 22 ± 2 (37) 16 ± 2 (35)
2 14 ± 3 (38) 23 ± 4 (38) 21 ± 3 (30) 20 ± 4 (41) 14 ± 4 (40)
3 13 ± 3 (41) 19 ± 3 (51) 21 ± 4 (29) 22 ± 5 (36) 10 ± 4 (57)
a Number of revertants; NQNO (nitroquinoline-N-oxide, 40 ng/mL) was used as a positive control; DMSO and H2O were used as a negative control; b the values in parenthesis are the 
inhibition rates (%) of mutagenicity; 25-40% inhibition: moderate antigenotoxicity, 40%; or more inhibition: strong antigenotoxicity, 25% or less inhibition: no antigenotoxicity.
2.4. P-gp Activity
An important approach in the evaluation of 1-3 was to determine their interaction with P-gp, 
which is an integral plasma membrane protein and functions as an ATP-dependent drug efflux 
pump [44,45]. It was demonstrated that P-gp is involved in MDR and some adverse drug-drug 
interactions [46,47]. P-gp-interacting pharmaceutical agents are recognized as stimulators or inhibitors 
of ATPase activity.
In the present experimeni, verapamil (VER), which 1  an inhibitor as well as a substrate of P-gp, 
was used as a positive control that stimulates P-gp ATPase activity (ATP consumption) [44]. In the 
presence of VER a P-gp-dependent decrease in luminescence was observed, whereas in the case of 
two enantiomers, an increase in luminescence was detected, which indicates a decrease in ATPase 
activity and, thus, inhibition of the P-gp .ATPase function (Figure 6). "Therefore, it was demonstrated 
that both enantiomers possess P-gp inhibition ability., with R ennntiomtr being more potent. It was 
demonstraten previously that P-ep can ioteract in a differene way with enantiomers [0e-5 0]. When 
chiral drugs modulate P-gp, oneenantiom er can increase the activity of the pump, while the other 
enantiomer can inhibit its activity [51,52].
Figure 6. Effects of 1 or 2 and verapamil (VER) on P-gp activity. P-gp ATPase activity was determined 
by using ths P-gp-Glo TM assay system, and AnP accumulation wai measured as luminescence in a 
cellular system in the absenco and in tire presepce of 100 pM verapamil (used as positive conirol for 
ATPase ectivity inhibition) or 1 or 2 at increasing concentrations (10, 25, 50, 75, or 100 pM).
In general, P-gp inhibition is related to three mechanisms: drug binding site blocking, influence 
on ATP hydrolysis, and modification of membrane lipid integrity [15]. Interestingly, such inhibition of 
P-gp may represent an approach to improving treatment efficiency, especially in the field of oncology 
or pharmacoresistant epilepsy [14,53- 58]. As regards both tested enantiomers, further studies are 
definitely needed in order to better understand their P-gp inhibition potential and possible MDR 
modulation potency.
3. Materials and Methods
3.1. Cytotoxicity Assays
3.1.1. Cell Culture
Astrocyte cell line (ATCC, CRL-2541), human glioblastoma astrocytoma cell line U373 (ATCC, 
HTB17-1055), and human hepatoma HepG2 cells (ATCC, HB-8065) were used in the study. The cells 
were cultured in standard conditions (37 °C, 5% CO2 ), in EMEM medium with 2 mM glutamine and 
1% non-essential amino acids, all supplemented with 10% FBS and antibiotics (penicillin-streptomycin; 
10,000 U/mL; final concentration in culture medium was 1%).
3.1.2. MTT Viability Test
The cells were seeded at a density of 1 X 104 in 96-well plates. Following overnight culture, the 
cells were treated with increasing doses of compounds 1-3 (i.e., 10 ,25 ,50 , or 100 gM) and incubated 
for 24 h. Next, 10 gL of MTT (3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) reagent 
(Cayman) was added to each well and after 3  h of incubation (37 °C, 5% CO 2 ) the medium was 
aspirated, and the formazan produced in the cells appeared as dark crystals at the bottom of the wells. 
Subsequently, crystal dissolving solution (Cayman) was added to each well and the optical density 
(OD) was determined at 570 nm on a plate reader (BIOTEK). Doxorubicin (DOX) was used as a positive 
control. When hepatotoxicity of test compounds was evaluated, the morphology of the cells was also 
determined using a bright-field inverted microscope (Nikon).
3.1.3. LDH Viability Test
The cells were seeded at a density of 1 X 104 in 96-well plates. Following overnight culture, the 
cells were treated with increasing doses of 1-3 (i.e., 10, 25, 50, or 100 gM) and incubated for 24 h. 
Subsequently, 100 gL of cell supernatant was transferred to a new 96-well plate and 100 gl of a reaction 
solution (Cayman) was added to each well. Cells were incubated for 30 min at 37 °C and absorbance 
was measured at 490 nm. The percent of cytotoxicity of the test samples was determined according to 
the following formula: ((experimental value A490) -  (spontaneous release))/((maximum release) -  
(spontaneous release)) X 100%, where spontaneous release is the absorbance origin from the control 
cells, and maximum release is the absorbance origin from the cells treated with TRITON-X-100.
3.1.4. Data Analysis
Data from the cytotoxicity assays were analyzed using M ann-W hitney U test with GraphPad 
Prism 4.0 Software (GraphPad Software Inc., San Diego, CA, USA). Values of p <  0.05 were considered 
to be statistically significant.
3.2. Metabolic Activation and Trapping Assay
3.2.1. Chemicals and Reagents
Human liver microsomes (HLMs), NADPH-regenerating system components, and reduced 
glutathione were purchased from Sigma-Aldrich (St Louis, MO, USA).
3.2.2. Human Liver Microsomal Biotransformation and Trapping Assay
The reaction systems (total volume of 250 gL) contained compounds 1 ,2 , or 3 (50 gM), glutathione 
(1 mM), HLMs (1 mg/mL),NADPH-regenerating system, and 0.1 M potassium phosphate buffer (pH 7.4). 
After 10 min preincubation at 37 °C, the reaction was started by adding the NADPH-regenerating system 
(NADP, glucose-6-phosphate, and glucose-6-phosphate dehydrogenase in a potassium phosphate 
buffer). Incubation was conducted for 60 min at 37 °C in a shaker. Then 70% perchloric acid was 
used to terminate the reaction. After centrifugation at 10,000 rpm for 10 min, the supernatant was 
collected and analyzed by UPLC-MS/MS (Waters Corporation, Milford, MA, USA) for direct analysis 
of glutathione adducts. Control reactions were carried out in the absence of glutathione. All probes 
were done in duplicate [59].
3.3. Mutagenicity and Antimutagenicity Assays
3.3.1. Chemicals and Reagents
The following chemicals and reagents were obtained from Sigma-Aldrich (St Louis, MO, USA): 
magnesium sulfate, citric acid monohydrate, potassium phosphate dibasic, sodium ammonium 
phosphate, L-histidine, D-biotin, sodium phosphate dibasic, sodium phosphate monobasic, magnesium 
chloride, potassium chloride, and 4-nitroquinoline-N-oxide (NQNO). Agar, bacto-peptone, and beef
extract were purchased from Merck (Darmstadt, Germany). D-Glucose, NaCl, and DMSO were obtained 
from Chempur (Piekary Śląskie, Poland), and nutrient broth no. 2 from Oxoid (Hampshire, UK). 
Glycerol and neomycin sulfate were purchased from Pharma Cosmetic (Krakow, Poland).
3.3.2. Bacterial Test Systems
S. typhimurium  TA100 strain was kindly provided by Dr. K.I. Sugiyama (National Institute of
Hygienic Sciences, Tokyo, Japan); V harveyi strains were a gift from Prof. G. Węgrzyn (Department of 
Molecular Biology, University of Gdańsk, Poland).
3.3.3. Ames Mutagenicity Testing
The Ames assay was conducted by the preincubation method using S. typhimurium  TA100 
strain [60]. Each probe was performed in triplicate; 100 gL of the overnight bacterial culture, 50 gL 
of the investigated compounds at a concentration of 40 ng/mL, and 500 gL of a buffer solution were 
preincubated for 30 min at 37 °C and then added to 2 mL of the top agar containing histidine/biotin 
solution . The resulting mixture was poured onto minimal glucose plates. After 48 h incubation, the 
revertants were counted manually and the results were expressed as mutagenic index (MI) (MI =  the 
number of revertant colonies induced in the tested sample/the number of spontaneous revertants in 
the negative control). The mutagenic potential of a test compound was stated if the mutant frequency 
was 2.0 or higher [61,62]. The standard mutagen used as a positive control was NQNO. DMSO served 
as the negative (solvent) control.
3.3.4. Vibrio harveyi Mutagenicity Testing
In the experiment, overnight cultures of bacterial strains BB7, BB7M, BB7X, and BB7XM were used. 
Each culture was centrifuged and 10 gL of V. harveyi pellets was placed in 20 mL of BOSS medium. 
The culture was cultivated at 30 °C until the optical density reached 0.1 at 600 nm (OD600). Then, 10 gL 
of test compound solution (final concentration of 40 ng/mL) was added to the bacterial culture and 
incubated. Incubation was continued until OD600 reached 0.3-0.4. Next, 5 X 106 bacterial cells were 
spread onto BOSS agar plates with neomycin. The plates were incubated at 30 °C for 48 h and the number 
of neomycin-resistant colonies was counted. As a positive control, NQNO was used, whereas DMSO 
and water served as negative controls [63- 65]. All the experiments were analyzed in three independent 
repetitions. Finally, MI was calculated. A compound was considered mutagenic if MI was equal or 
greater than 2.0 [61,62].
3.3.5. Ames Antimutagenicity Testing
The antimutagenic properties of compounds 1-3 were assayed in S. typhimurium  TA100 strain 
against NQNO with a modified method of Maron and Ames [60].
Triplicate plates were set up with each test compound concentration and the entire experiment 
was repeated twice. The inhibition of mutagenicity was expressed as a percentage decrease of reverse 
mutation, calculated using the following equation: percent inhibition =  100 -  ((Ri/R2) X 100), where Rx 
is the number of revertants per plate induced by test compound plus mutagen, and R 2 is the number 
of revertants per plate induced by a mutagen alone; 25-40%  inhibition was defined as moderate 
antimutagenicity, 40% or higher inhibition was defined as strong antimutagenicity, and 25% or less 
inhibition indicated no antimutagenicity [66,67].
3.3.6. Vibrio harveyi Antimutagenicity Testing
The antimutagenicity assay was conducted according to the same procedure as used for the 
mutagenicity assay, except that the standard mutagen was also added to the bacterial cultures incubated 
with test compounds [65]. The inhibition percentage of mutagenicity was calculated as described above 
in the Ames antimutagenicity assay procedure.
3.4. P-gp ATPase Activity Assay
The changes in the ATPase activity of P-gp were determined by using the P-gp-Glo TM assay 
system (Promega). Verapamil (VER) was used as a positive control since it inhibits P-gp ATPase 
activity, which eventually leads to reduced drug efflux. When P-gp ATPase activity is inhibited, ATP 
accumulates and becomes a substrate for luciferase, with a consequent increase in luminescence. 
The tested compounds at increasing concentration (10-100 gM) were incubated with 5 mM Mg ATP 
and 25 gg recombinant human P-gp membranes at 37 °C for 45 min. The luminescence signal was 
started by adding ATP detection buffer. After incubation at room temperature for 25 min, the samples 
were read in white 96-well plates on a multi-plate reader (BIOTEK).
4. Conclusions
Compounds 1-3 were designed and synthesized based on a trans-2-aminocyclohexan-1-ol structure. 
Previous investigations have indicated the anticonvulsant potency of these compounds. Additionally, 
in vitro metabolism of 1-3 via liver microsomes and a microbial model (Cunninghamella) was performed. 
To complement the above results, in the present study the safety profile of both enantiomers and 
a racemate (1-3) was evaluated, including their cytotoxicity, mutagenicity, and reactive metabolite 
formation potential. Moreover, their antimutagenic activity and the effect on P-gp ATPase were examined.
The obtained results revealed that the newly synthesized active chiral N -aminoalkyl derivatives 
of trans-2-aminocyclohexan-1-ol may be promising candidates for further research focused on the 
discovery and development of anticonvulsant agents. All tested compounds demonstrated their 
promising anticancer properties on the glioblastoma cells U373. Furthermore, the P-gp ATPase assay 
demonstrated that both enantiomers are potent P-gp inhibitors as they inhibit P-gp ATPase activity. This 
new application of compounds 1-3 is also attractive due to their mutagenic safety, low bioactivation 
potential, and important antimutagenic activity. These results might be of great potential interest in 
the design of new antiepileptic compounds.
Finally, our study indicated the similar safety profile of the enantiomeric N-aminoalkyl derivatives 
of trans-2-aminocyclohexan-1-ol, although in the previous studies both enantiomers differ in their 
biotransformation pathways and pharmacological activity.
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